# Host Response Mediators in Coronavirus (COVID-19) Infection - Is There a Protective Effect of Losartan and Other ARBs on Outcomes of Coronavirus Infection?

> **NCT04606563** · PHASE3 · TERMINATED · sponsor: **University of British Columbia** · enrollment: 341 (actual)

## Conditions studied

- Covid19
- SARS-CoV Infection

## Interventions

- **DRUG:** Losartan
- **DRUG:** Valsartan
- **DRUG:** Azilsartan
- **DRUG:** Candesartan
- **DRUG:** Eprosartan
- **DRUG:** Irbesartan
- **DRUG:** Olmesartan
- **DRUG:** Telmisartan

## Key facts

- **NCT ID:** NCT04606563
- **Lead sponsor:** University of British Columbia
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-10-09
- **Primary completion:** 2022-04-22
- **Final completion:** 2022-04-22
- **Target enrollment:** 341 (ACTUAL)
- **Why stopped:** DSMC recommendation due to futility
- **Last updated:** 2023-02-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04606563

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04606563, "Host Response Mediators in Coronavirus (COVID-19) Infection - Is There a Protective Effect of Losartan and Other ARBs on Outcomes of Coronavirus Infection?". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04606563. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*